Mineralys Therapeutics, Inc. 8-K

What Happened

• Mineralys Therapeutics (MLYS) filed an 8-K (March 9, 2026) reporting FDA acceptance of its New Drug Application (NDA) for lorundrostat for treatment of adult hypertension in combination with other antihypertensive drugs. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
• The company also reported topline results from the Phase 2 Explore‑OSA exploratory trial (48 participants). Lorundrostat 50 mg taken in the evening did not show a clinically meaningful improvement versus placebo on the trial’s primary endpoint (apnea-hypopnea index, AHI) after four weeks. The trial did show blood-pressure effects: a 11.1 mmHg reduction with lorundrostat (p < 0.0001) versus a 1.0 mmHg reduction with placebo (p = NS) in a pre-planned parallel-arm analysis of the first period, and a 6.2 mmHg placebo‑adjusted reduction (p < 0.0003) in a crossover analysis. Lorundrostat was well tolerated with no serum potassium values above 5.5 mmol/L. Additional endpoint analyses are ongoing.

Key Details

• NDA acceptance notified by FDA on March 6, 2026; PDUFA date: December 22, 2026.
• Explore‑OSA: n = 48; mean BMI = 38.2 kg/m2; mean baseline AHI = 48.5 events/hr; mean baseline systolic BP = 142.3 mmHg (range 131–175).
• Efficacy: no clinically meaningful change vs placebo on AHI (primary); BP reductions: 11.1 mmHg (lorundrostat) vs 1.0 mmHg (placebo), placebo‑adjusted −6.2 mmHg in crossover (statistically significant p‑values noted).
• Safety: favorable profile reported; no serum potassium > 5.5 mmol/L; further analyses and future reports planned.

Why It Matters

• FDA acceptance of the NDA establishes a clear regulatory review pathway and a December 22, 2026 timeline for a decision, which is a key near‑term milestone for potential commercialization in hypertension.
• Positive blood‑pressure effects and a favorable safety readout support the hypertension development program and the NDA filing, but the lack of a meaningful effect on AHI indicates lorundrostat did not meet the Explore‑OSA trial’s primary sleep‑apnea endpoint—important for any OSA-related claims.
• Ongoing analyses and upcoming publications or medical‑meeting presentations may provide additional data that could affect investor perception and the drug’s commercial prospects.